Maria
Sundvall
Docent, Institute of Biomedicine
Clinical Lecturer, Institute of Biomedicine
MD PhD; Specialist Physician in Clinical Oncology
Areas of expertise
clinical oncology
breast and prostate cancer
targeted cancer therapeutics
cancer biology
cell signaling
posttranslational modifications
dna repair pathways
Biography
Maria Sundvall received her MD degree from the University of Turku in 2003, and defended her PhD thesis at the Department of Medical Biochemistry and Genetics, University of Turku, in 2007. From 2011 she worked nearly 4 years as a postdoctoral fellow in the laboratory of Prof. Pier Paolo Pandolfi, Beth Israel Deaconess Medical Center, Harvard Medical School, Boston, USA. After returning to Finland in 2015 she established her own research group at the University of Turku. Dr. Sundvall received a specialist physician degree in clinical oncology in 2018. Since 2018 Dr. Sundvall has worked as a part-time clinical lecturer at the Institute of Biomedicine, a part-time Academy of Finland clinical researcher and a part-time specialist physician in clinical oncology at Turku University Hospital.
Teaching
Dr. Sundvall has several years of experience in teaching medical students as a clinical lecturer and a university teacher in the fields of medical biochemistry, molecular medicine and cancer during the last 15 years.
Research
Dr. Sundvall has 20 years of experience in studying molecular mechanisms of cancer. Currently she is a principal investigator at University of Turku, and her group is focusing on investigating the role fo DNA repair pathways in prostate cancer. Links:
https://www.utu.fi/en/university/faculty-of-medicine/institute-of-biomedicine/research/cancer-research
https://www.utu.fi/en/university/faculty-of-medicine/institute-of-biomedicine/research/cancer-research
Publications
xCT as a Predictor for Survival in a Population‐Based Cohort of Head and Neck Squamous Cell Carcinoma (2024)
Cancer Medicine
(A1 Vertaisarvioitu alkuperäisartikkeli tieteellisessä lehdessä )
TIMP-1 is an activator of MHC-I expression in myeloid dendritic cells with implications for tumor immunogenicity (2024)
Genes and Immunity
(A1 Vertaisarvioitu alkuperäisartikkeli tieteellisessä lehdessä )
Phage Biosensor for the Classification of Metastatic Urological Cancers from Urine (2024)
Life
(A1 Vertaisarvioitu alkuperäisartikkeli tieteellisessä lehdessä )
TSPO is a potential independent prognostic factor associated with cellular respiration and p16 in head and neck squamous cell carcinoma (2023)
Frontiers in Oncology
(Vertaisarvioitu alkuperäisartikkeli tai data-artikkeli tieteellisessä aikakauslehdessä (A1))
Effect of caldesmon mutations in the development of zebrafish embryos (2023)
Biochemical and Biophysical Research Communications
(Vertaisarvioitu alkuperäisartikkeli tai data-artikkeli tieteellisessä aikakauslehdessä (A1))
Glucocorticoid receptor-induced non-muscle caldesmon regulates metastasis in castration-resistant prostate cancer (2023)
Oncogenesis
(Vertaisarvioitu alkuperäisartikkeli tai data-artikkeli tieteellisessä aikakauslehdessä (A1))
Radium-223 dichloride treatment in metastatic castration-resistant prostate cancer in Finland: A real-world evidence multicenter study (2022)
Cancer Medicine
(Vertaisarvioitu alkuperäisartikkeli tai data-artikkeli tieteellisessä aikakauslehdessä (A1))
More Than Meets the Eye: Scientific Rationale behind Molecular Imaging and Therapeutic Targeting of Prostate-Specific Membrane Antigen (PSMA) in Metastatic Prostate Cancer and Beyond (2021)
Cancers
(Vertaisarvioitu katsausartikkeli tieteellisessä aikakauslehdessä (A2))
Ex vivo -mallit ja nestebiopsia yksilöllistetyssä syövänhoidossa (2021)
Duodecim
(Vertaisarvioitu katsausartikkeli tieteellisessä aikakauslehdessä (A2))
Therapeutic Potential of Targeting the SUMO Pathway in Cancer (2021)
Cancers
(Vertaisarvioitu katsausartikkeli tieteellisessä aikakauslehdessä (A2))